Skip to NavigationSkip to content

BARDA

Renewed BARDA backing boosts J&J’s COVID-19 vaccine funding by $1bn

Johnson & Johnson has said that it is injecting around $1 billion of funding into its research efforts to develop a COVID-19 vaccine, part of that sum coming from the US Government.

In an expansion of its current partnership with the Biomedical Advanced Research and Development Authority (BARDA), J&J is set to receive an additional $454 million from the authority to fund its ongoing Phase 3 studies of its adenovirus-based vaccine candidate in a single-dose formulation – a key factor that sets it apart from rival therapies from Moderna and Pfizer and BioNTech.

Regeneron seals $450m BARDA contract to scale up production of its COVID-19 vaccine

Regeneron has revealed that REGN-COV2, its two-antibody vaccine for the treatment and prevention of COVID-19, has been awarded a manufacturing and supply funding contract to the value of $450 million from the Biomedical Advanced Research and Development Authority (BARDA) as part of the US Government’s Operation Warp Speed programme to accelerate development and access to the most promising prophylactics against the novel coronavirus.

The contract concerns Regeneron, BARDA, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclea

Ousted chief of BARDA says Trump administration ignored COVID-19 warnings

Photo by Joyce N. Boghosian

Ousted Director of the Biomedical Advanced Research and Development Authority (BARDA), Dr Rick Bright, alleges the Trump administration ignored warnings about the severity of the coronavirus.

Much of his complaints, and what he believes led to him being ousted, was the administration pushing hydroxychloroquine and chloroquine as a coronavirus treatment.

Pharmafile.com's weekly COVID-19 news round-up

Photo by CDC

Hydroxychloroquine continues to feature in coronavirus news. Rick Bright, the Director of BARDA, alleges he was pushed out of his position due to his pushback to the administration focusing on the use of hydroxychloroquine in COVID-19 patients. This came after the National Institutes of Health said coronavirus patients should not take the drug due to potential “toxicities.”

Researchers have also been investigating the heartburn drug Pepcid, as a potential treatment, while the FDA has granted emergency clearance for the first in-home testing kit.

US Government's BARDA to fund Moderna's coronavirus vaccine by $483m

Moderna has secured $483 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), to drive development and availability of its messenger RNA (mRNA) vaccine candidate against the novel coronavirus.

The agreement means that BARDA, a division of the US Department of Health and Human Services (HHS), will finance the development of Moderna’s candidate, known as mRNA-1273, to secure approval from the FDA with the aim of making the therapy accessible US citizens as soon as possible once its safety and efficacy can be proven.

Bavarian Nordic seals $539 million vaccine deal

Bavarian Nordic, a Danish biotech, has continued its partnership with the US government by agreeing a $539 million deal to deliver smallpox vaccines. The partnership between Bavarian Nordic will see it provide the Biomedical Advanced Research and Development Authority (BARDA) with a freeze-dried formulation of the vaccine.

Sanofi secures $43 million government funding for zika vaccine development

The US Department of Health and Human Services approved $43.18 million to fund Sanofi’s development of a zika vaccine, the company has announced.

AstraZeneca and US Government collaborate to develop new antibiotics

AstraZeneca_drug_discovery
AstraZeneca is developing antibiotics with the US Department of Health and Human Services is (Credit:AZ)

AstraZeneca has entered into a public-private partnership with the US Department of Health and Human Services to develop drugs to combat bacterial infections.

The agreement is the second alliance the US Government’s Biomedical Advanced Research and Development Authority (BARDA) has forged with a private company to develop a portfolio of drug candidates with dual uses – treating illnesses caused by antibiotic-resistant infections, as well as those caused by bioterrorism agents.

GSK gets $200m from White House

GSK image

GlaxoSmithKline is to be given up to $200 million by the US government to develop new antibiotics as worries grow over the increasing threat of antimicrobial resistance (AMR).

 

GSK will get the money from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and Human Services (HHS).

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches